Lisata Therapeutics Future Growth
Future criteria checks 0/6
Lisata Therapeutics's earnings are forecast to decline at 7.9% per annum while its annual revenue is expected to grow at 85.7% per year. EPS is expected to grow by 11.5% per annum.
Key information
-7.9%
Earnings growth rate
11.5%
EPS growth rate
Biotechs earnings growth | 20.7% |
Revenue growth rate | 85.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 01 Mar 2024 |
Recent future growth updates
Recent updates
Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?
Mar 22We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
Sep 15Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Sep 14Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01
Aug 04We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully
May 02We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate
Jan 05Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth
May 09Caladrius suspends CLBS119 COVID-19 study
Dec 14Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation
Nov 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -28 | N/A | N/A | 2 |
12/31/2025 | N/A | -30 | N/A | N/A | 2 |
12/31/2024 | N/A | -26 | N/A | N/A | 2 |
12/31/2023 | N/A | -21 | -20 | -20 | N/A |
9/30/2023 | N/A | -21 | -22 | -22 | N/A |
6/30/2023 | N/A | -54 | -23 | -23 | N/A |
3/31/2023 | N/A | -56 | -24 | -24 | N/A |
12/31/2022 | N/A | -54 | -21 | -21 | N/A |
9/30/2022 | N/A | -55 | -20 | -19 | N/A |
6/30/2022 | N/A | -25 | -21 | -20 | N/A |
3/31/2022 | N/A | -24 | -20 | -20 | N/A |
12/31/2021 | N/A | -27 | -22 | -22 | N/A |
9/30/2021 | N/A | -26 | -23 | -23 | N/A |
6/30/2021 | N/A | -25 | -22 | -22 | N/A |
3/31/2021 | N/A | -12 | -13 | -13 | N/A |
12/31/2020 | N/A | -8 | -9 | -9 | N/A |
9/30/2020 | N/A | -8 | -7 | -7 | N/A |
6/30/2020 | N/A | -7 | -8 | -8 | N/A |
3/31/2020 | N/A | -19 | -18 | -18 | N/A |
12/31/2019 | N/A | -19 | -19 | -19 | N/A |
9/30/2019 | N/A | -18 | -18 | -18 | N/A |
6/30/2019 | N/A | -17 | -18 | -18 | N/A |
3/31/2019 | N/A | -16 | -19 | -19 | N/A |
12/31/2018 | N/A | -16 | -20 | -20 | N/A |
9/30/2018 | N/A | -17 | -21 | -21 | N/A |
6/30/2018 | N/A | -17 | -23 | -22 | N/A |
3/31/2018 | N/A | -14 | -17 | -17 | N/A |
12/31/2017 | N/A | -16 | -21 | -21 | N/A |
9/30/2017 | N/A | -18 | N/A | -20 | N/A |
6/30/2017 | N/A | -20 | N/A | -20 | N/A |
3/31/2017 | -7 | -26 | N/A | -26 | N/A |
12/31/2016 | N/A | -31 | N/A | -24 | N/A |
9/30/2016 | 8 | -59 | N/A | -29 | N/A |
6/30/2016 | 13 | -64 | N/A | -32 | N/A |
3/31/2016 | 27 | -74 | N/A | -33 | N/A |
12/31/2015 | 22 | -81 | N/A | -39 | N/A |
9/30/2015 | 20 | -59 | N/A | -41 | N/A |
6/30/2015 | 18 | -65 | N/A | -46 | N/A |
3/31/2015 | 17 | -60 | N/A | -50 | N/A |
12/31/2014 | 18 | -55 | N/A | -47 | N/A |
9/30/2014 | 17 | -56 | N/A | -43 | N/A |
6/30/2014 | 16 | -48 | N/A | -36 | N/A |
3/31/2014 | 16 | -44 | N/A | -31 | N/A |
12/31/2013 | 15 | -39 | N/A | -27 | N/A |
9/30/2013 | 13 | -39 | N/A | -29 | N/A |
6/30/2013 | 14 | -40 | N/A | -26 | N/A |
3/31/2013 | 13 | -38 | N/A | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LSTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LSTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LSTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LSTA is forecast to have no revenue next year.
High Growth Revenue: LSTA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LSTA's Return on Equity is forecast to be high in 3 years time